Investigational drugs for sickle cell disease and diffuse large B cell lymphoma from Global Blood Therapeutics and Roche respectively have become the latest products to make it onto the European Medicines Agency’s PRIME scheme for speeding the development of drugs for unmet medical need.
The European Medicines Agency has accepted the first investigational drug for treating sickle cell disease (SCD) onto its priority medicines (PRIME) program for getting products for unmet medical needs to patients faster.
GBT440 is being develop by Global Blood Therapeutics, which has met PRIME’s rigorous entry criteria and will now receive early and proactive support from the EMA to help optimize its development
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.
